1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | August 19, 2024 at 09:00:00 EEST

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc ("BBS") has received on August 16, 2024 requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 75,942.20 of the convertible notes into Company shares at a conversion price of EUR 0.27432 per share. The conversion shall be executed by transferring a total of 276,838 treasury shares to Riverfort.

The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.

After the transfer, the Company will not hold treasury shares in its possession.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

Datum 2024-08-19, kl 08:00
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
Affiliate
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet